201 related articles for article (PubMed ID: 27352261)
1. CALR mutation profile in Irish patients with myeloproliferative neoplasms.
Haslam K; Conneally E; Flynn CM; Cahill MR; Gilligan O; O'Shea D; Langabeer SE
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):112-5. PubMed ID: 27352261
[TBL] [Abstract][Full Text] [Related]
2. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
3. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
[TBL] [Abstract][Full Text] [Related]
6. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
7. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
Wang J; Hao J; He N; Ji C; Ma D
Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
[TBL] [Abstract][Full Text] [Related]
8. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A
Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692
[TBL] [Abstract][Full Text] [Related]
9. [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].
Tang Q; Zhang XW; Xia L; Jiang NK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):151-156. PubMed ID: 28245393
[TBL] [Abstract][Full Text] [Related]
10. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.
Tefferi A; Thiele J; Vannucchi AM; Barbui T
Leukemia; 2014 Jul; 28(7):1407-13. PubMed ID: 24441292
[TBL] [Abstract][Full Text] [Related]
11. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
Nomani L; Bodo J; Zhao X; Durkin L; Loghavi S; Hsi ED
Am J Clin Pathol; 2016 Oct; 146(4):431-8. PubMed ID: 27686170
[TBL] [Abstract][Full Text] [Related]
12. The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in
Pan Y; Wang X; Wen S; Liu X; Yang L; Luo J
Hematology; 2022 Dec; 27(1):902-908. PubMed ID: 36000955
[TBL] [Abstract][Full Text] [Related]
13. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
Pathology; 2019 Apr; 51(3):301-307. PubMed ID: 30606612
[TBL] [Abstract][Full Text] [Related]
14. A novel molecular assay using hybridisation probes and melt curve analysis for
Keaney T; O'Connor L; Krawczyk J; Abdelrahman MA; Hayat AH; Murray M; O'Dwyer M; Percy M; Langabeer S; Haslam K; Glynn B; Mullen C; Keady E; Lahiff S; Smith TJ
J Clin Pathol; 2017 Aug; 70(8):662-668. PubMed ID: 28143941
[TBL] [Abstract][Full Text] [Related]
15. Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.
Kjær L; Cordua S; Holmström MO; Thomassen M; Kruse TA; Pallisgaard N; Larsen TS; de Stricker K; Skov V; Hasselbalch HC
PLoS One; 2016; 11(10):e0165336. PubMed ID: 27764253
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
17. Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.
Mehrotra M; Luthra R; Singh RR; Barkoh BA; Galbincea J; Mehta P; Goswami RS; Jabbar KJ; Loghavi S; Medeiros LJ; Verstovsek S; Patel KP
Am J Clin Pathol; 2015 Nov; 144(5):746-55. PubMed ID: 26486739
[TBL] [Abstract][Full Text] [Related]
18. Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms.
Cavalloni C; Rumi E; Ferretti VV; Pietra D; Roncoroni E; Bellini M; Ciboddo M; Casetti IC; Landini B; Fugazza E; Troletti D; Astori C; Cazzola M
Oncotarget; 2017 May; 8(20):33416-33421. PubMed ID: 28422716
[TBL] [Abstract][Full Text] [Related]
19. Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.
Andrici J; Farzin M; Clarkson A; Sioson L; Sheen A; Watson N; Toon CW; Koleth M; Stevenson W; Gill AJ
Pathology; 2016 Jun; 48(4):319-24. PubMed ID: 27114372
[TBL] [Abstract][Full Text] [Related]
20. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Martin S; Wright CM; Scott LM
Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]